What is MDSAP?
The Medical Device Single Audit Program (MDSAP) is an initiative in which the five Regulatory Authority Council (RAC) countries, including Japan, jointly oversee Quality Management System (QMS) audits and utilize the QMS audit results provided by these auditing organizations across each RAC member country. In addition to the RAC, there are also Official Observers and Affiliate Members, with their respective countries (regulators) and roles outlined below.
Regulatory Authority Council (RAC):
Japan (MHLW and PMDA), Australia (TGA), Brazil (ANVISA), Canada (HC), and the United States (FDA)
Serves as the decision-making body of MDSAP for providing direction, oversight, and resources to support the MDSAP development, implementation, maintenance, and expansion.
Official Observer:
European Union (EU), Singapore (HSA), United Kingdom (MHRA), and World Health Organization (WHO)
Monitors RAC activities and communicates recommendations and concerns regarding any RAC decisions.
Affiliate Member:
Argentina (ANMAT), Israel (Ministry of Health), Kenya (PPB), Republic of Korea (MFDS), Mexico (COFEPRIS), South Africa (SAHPRA), and Taiwan (TFDA)
Gains a clear understanding of MDSAP and uses MDSAP audit reports and/or MDSAP certificates to evaluate a manufacturer’s QMS within the regulatory framework of the respective country.
Top of Page
Acquiring MDSAP and its benefits
Currently, only QMS audits using MDSAP are accepted for Class II or higher medical products in Canada. In the other four countries (Japan, Australia, Brazil, and the United States), MDSAP is optional; nonetheless, the RAC member countries continue to utilize MDSAP QMS audits.
Therefore, a manufacturer that is selling products in three countries, such as Japan, Australia, and the United States, will only need to undergo one QMS survey instead of three. In addition, manufacturers are free to select their preferred auditing organization from the accredited list.
Note that, in affiliate member countries, MDSAP audit reports and certificates are utilized for evaluations as defined by the methods specified by those countries, thereby alleviating the burden on manufacturers.
Top of Page
QMS standards across regulatory authorities
The QMS standards set by each regulatory authority include requirements that are unique to their respective countries and those aligned with ISO 13485.
The regulations for each country are listed below.
Japan (PMDA)
Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Medical Devices and In-Vitro Diagnostics (QMS Ordinance No. 169)
Australia (TGA)
Therapeutic Goods (Medical Devices) Regulations 2002 – Schedule 3: Conformity Assessment Procedures (TG(MD)R Sch3)
Brazil (ANVISA)
Collegiate Board Resolution – RDC NO. 665 OF 30 MARCH 2022: Good Manufacturing Practices for Medical Products and In Vitro Diagnostic Products (RDC ANVISA 665/2022)
Canada (HC)
CSA ISO 13485:16 (R2021) Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes
U.S. (FDA)
Code of Federal Regulations Title 21 – PART 820—Quality System Regulation (21 CFR Part 820)
*The new Quality Management System Regulation (QMSR) will take effect on February 2, 2026.
Top of Page
Auditing Organization
MDSAP audits are only conducted by auditing organizations accredited by the RAC.
Below is a list of auditing organizations that are currently approved.
Auditing Organization Availability to Conduct MDSAP Audits
Top of Page
Audit Approach
MDSAP audits are conducted in accordance with the document ”MDSAP Audit Approach.” This document describes specific methods used by auditing organizations to conduct MDSAP audits, as detailed in the following chapters.
- Chapter 1 – Management
- Chapter 2 – Device Marketing Authorization and Facility Registration
- Chapter 3 – Measurement, Analysis and Improvement
- Chapter 4 – Medical Device Adverse Events and Advisory Notices Reporting
- Chapter 5 – Design and Development
- Chapter 6 – Production and Service Controls
- Chapter 7 – Purchasing
Within each chapter, detailed explanations are referred to as “Tasks,” and the mappings to each country’s regulations and any specific additional requirements (differences) are also clarified.
Bear in mind that when using MDSAP, it is necessary to include all RAC member countries to which products will be shipped. Note that the regulatory requirements of RAC member countries where products will not be shipped are deemed unnecessary. Specifically, if shipping to Japan and Canada, MDSAP cannot be used solely for Canada; instead, an MDSAP audit is required for both Japan and Canada.
At SunFlare, we provide expert consulting services to help clients obtain MDSAP certification.
Top of Page
MDSAP audit cycle
After the initial full-scope QMS audit, partial surveillance audits are conducted annually for the first two years. In the third year, a full-scope re-audit, also commonly referred to as a recertification audit (renewal review), is conducted.
SunFlare also offers consulting services pertaining to any updates in the MDSAP Audit Approach.
Top of Page
Consulting services provided by SunFlare
To obtain MDSAP certification, SunFlare offers the following support services:
- Lectures on MDSAP requirements
- Consulting on decision-making regarding the use of MDSAP
- Gap analysis between the requirements and your current status
- Consulting on the development of a quality management system and creation of QMS-related documents, based on the use of MDSAP
- Consulting on operational support for quality management systems using MDSAP
Top of Page